This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Madrigal (MDGL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Madrigal (MDGL) delivered earnings and revenue surprises of +45.40% and +32.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Profound Medical (PROF) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Profound Medical (PROF) delivered earnings and revenue surprises of -24.14% and 24.03%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Profound Medical (PROF): Can Its 8.3% Jump Turn into More Strength?
by Zacks Equity Research
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Profound Medical (PROF) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Profound Medical (PROF) delivered earnings and revenue surprises of 33.33% and 0.55%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Rigel Pharmaceuticals (RIGL) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Rigel (RIGL) delivered earnings and revenue surprises of 45.45% and 0.02%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Profound Medical (PROF) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Profound Medical (PROF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Does Profound Medical (PROF) Have the Potential to Rally 100.13% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 100.1% in Profound Medical (PROF). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Profound Medical (PROF) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Profound Medical (PROF) delivered earnings and revenue surprises of -15.15% and 14.18%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Predict a 106.45% Upside in Profound Medical (PROF): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 106.5% upside potential for Profound Medical (PROF). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Profound Medical (PROF) Moves 5.1% Higher: Will This Strength Last?
by Zacks Equity Research
Profound Medical (PROF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Profound Medical (PROF) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Profound Medical (PROF) delivered earnings and revenue surprises of 0% and 10.68%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Catalyst Pharmaceutical (CPRX) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Catalyst (CPRX) delivered earnings and revenue surprises of 33.33% and 9.80%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Profound Medical (PROF) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Profound Medical (PROF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neurocrine Biosciences (NBIX) Lags Q2 Earnings Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of -45.22% and 7.56%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
United Therapeutics (UTHR) Misses Q2 Earnings Estimates
by Zacks Equity Research
United Therapeutics (UTHR) delivered earnings and revenue surprises of -7.58% and 4.66%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Profound Medical (PROF) Surges 6.0%: Is This an Indication of Further Gains?
by Zacks Equity Research
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Profound Medical (PROF) Adds AI to Prostate Cancer Treatment
by Zacks Equity Research
Profound Medical's (PROF) Contouring Assistant integrates AI into prostate cancer procedures, thereby streamlining the treatment planning process and enhancing both efficiency and precision.
ElectroCore, Inc. (ECOR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
electroCore (ECOR) delivered earnings and revenue surprises of -6% and 5.08%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Profound Medical (PROF), Siemens Unite to Treat Prostate Cancer
by Zacks Equity Research
Profound Medical (PROF) collaborates with Siemens to boost prostate cancer treatment procedures by combining their technologies.
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -33.90% and 20.83%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Profound Medical (PROF) Soars 9.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
How Much Upside is Left in Profound Medical (PROF)? Wall Street Analysts Think 66.06%
by Zacks Equity Research
The mean of analysts' price targets for Profound Medical (PROF) points to a 66.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Strength Seen in Profound Medical (PROF): Can Its 19.5% Jump Turn into More Strength?
by Zacks Equity Research
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Profound Medical (PROF) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Profound Medical (PROF) delivered earnings and revenue surprises of -12.90% and 21.85%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
What Makes Profound Medical (PROF) a New Buy Stock
by Zacks Equity Research
Profound Medical (PROF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.